Invasive fungal infections cause 1.6 million deaths annually, primarily in immunocompromised individuals. Mortality rates are as high as 90% due to limited number of efficacious drugs and poor drug availability. The azole class antifungal, fluconazole, is widely available and has multi-species activity but only inhibits fungal cell growth instead of killing fungal cells, necessitating long treatments. To improve fluconazole treatments, we used our novel high-throughput method, the overlap 2 method (O2M), to identify drugs that interact with fluconazole, either increasing or decreasing efficacy. Although serendipitous identification of these interactions is rare, O2M allows us to screen molecules five times faster than testing combinations individually and greatly enriches for interactors. We identified 40 molecules that act synergistically (amplify activity) and 19 molecules that act antagonistically (decrease efficacy) when combined with fluconazole. We found that critical frontline beta-lactam antibiotics antagonize fluconazole activity. A promising fluconazole-synergizing anticholinergic drug, dicyclomine, increases fungal cell permeability and inhibits nutrient intake when combined with fluconazole. In vivo, this combination doubled the time-to-endpoint of mice with disseminated Cryptococcus neoformans infections. Thus, our ability to rapidly identify synergistic and antagonistic drug interactions can potentially alter the patient outcomes.
Introduction
Invasive fungal infections are an increasing problem worldwide, contributing to 1.6 million deaths annually (Almeida et al., 2019; Bongomin et al., 2017; Brown et al., 2012) . These problematic infections are difficult to treat for many reasons. Delayed diagnoses, the paucity and toxicity of antifungal drugs, and the already immunocompromised state of many patients result in mortality rates of up to 90% (Brown et al., 2012; Pianalto and Alspaugh, 2016; Scorzoni et al., 2017) . To date, there are only four classes of antifungals, which primarily target the fungal cell envelope (cell wall and plasma membrane) (Coelho and Casadevall, 2016; Odds et al., 2003; Pianalto and Alspaugh, 2016; Scorzoni et al., 2017) . The population of immunocompromised individuals is growing due to medical advancements, such as immunosuppression for transplants and chemotherapy. Emerging fungal pathogens are simultaneously increasing in both clinical burden and the number of causal species due to human activity such as agricultural drug use (Berger et al., 2017) and global warming (Almeida et al., 2019; Garcia-Solache and Casadevall, 2010) . Thus, the need for more and better antifungal therapeutics is evident. hypothesis, we examined whether nafcillin affects ergosterol biosynthesis. We extracted sterols from C. neoformans cells grown in the presence of nafcillin, FLZ, nafcillin + FLZ, or vehicle. We found a concentration-dependent increase in ergosterol with nafcillin treatment (Fig. 4P) . Ergosterol levels in nafcillin + FLZ are not statistically different from the control treatment ( Fig.  4P ). Finally, we tested whether nafcillin is synergistic with the antifungal amphotericin B. Since amphotericin B kills target cells by binding and extracting ergosterol from the plasma membrane (Anderson et al., 2014) , we hypothesized that if nafcillin increases ergosterol levels in C. neoformans, nafcillin would act synergistically with amphotericin B by increasing amphotericin B binding sites (i.e. ergosterol). Indeed, amphotericin B was synergistic with nafcillin in checkerboard assays (Fig. 4Q) , further suggesting that nafcillin increases ergosterol levels in C. neoformans.
The synergistic interaction between dicyclomine HCl and FLZ affects cell permeability and nutrient uptake
Finally, we investigated the drug dicyclomine HCl (dicyclomine), an anticholinergic agent (Table 1) . This FDA-approved drug, also known as Bentyl, is used to treat urinary incontinence (Malone and Okano, 1999; Page and Dirnberger, 1981) . In humans it targets a G-protein coupled receptor (GPCR) encoded by the CHRM1 gene (Consortium, 2018; Kilbinger and Stein, 1988) . C. neoformans does not have a CHRM1 ortholog, but there are a large number GPCR in fungi that could be potential targets (Xue et al., 2008) . When we screened a deletion library of C. neoformans for mutants resistant to dicyclomine, we found that 44% of the annotated dicyclomine-resistant mutants were involved in transport and trafficking, suggesting that those processes may be related to dicyclomine's mechanism ( Fig. 6A and Table S5 ). Thus, we hypothesized that dicyclomine alters Golgi transport. In Saccharomyces cerevisiae, simultaneously inhibiting Golgi trafficking and blocking ergosterol synthesis leads to mislocalization of essential plasma membrane transporters (Estrada et al., 2015) . We hypothesized that the combination of dicyclomine and FLZ will phenocopy this effect in C. neoformans (Fig. 6B) . Using propidium iodide internalization as a measure of cell permeability, we observed that dicyclomine, similar to FLZ, permeabilizes fungal cells at high doses ( Fig. 6C,  D, F, G) . Furthermore, we saw a greater than additive increase in permeability when fungal cells were treated with low concentrations of dicyclomine and FLZ in combination ( Fig. 6E and H) . dicyclomine-induced permeability appeared to be independent of significant changes to cell wall chitin ( Fig. S4A-F) .
We next tested if dicyclomine + FLZ disrupted nutrient transporter function by measuring uptake of amino acids. If amino acid permeases are not localized to the plasma membrane, fungal cells are resistant to toxic amino acid analogs (Roberg et al., 1997) . Using the same low doses of FLZ and DIC that alone do not permeabilize cells, C. neoformans is susceptible to the effect of either 5-fluoroanthranilic acid (5-FAA) or 5-methyl-tryptophan (5-MT). When the dose is combined, cells now show resistance (Fig. 6I-L and Fig. S4G-J) . This demonstrates that certain amino acid transporters' function is decreased and they thus may be mislocalized, conferring resistance to toxic forms of tryptophan.
Dicyclomine + FLZ act synergistically in vivo and enhances survival of mice with cryptococcosis
We intranasally inoculated CD-1 outbred mice (Charles River) with C. neoformans and allowed the infection to progress 8 days. Colony forming unit data indicated that at this point 100% of the mice exhibited fungal dissemination to the liver, and 40% exhibited dissemination to the brain (Fig. S5) . A disseminated infection is consistent with human patients at treatment onset, as patients often don't seek treatment until C. neoformans has disseminated to the brain (Zhu et al., 2010) . From 8 days post-inoculation (d.p.i) until 40 d.p.i., we administered dicyclomine, FLZ, dicyclomine + FLZ or PBS (vehicle) intraperitoneally. We used doses of both FLZ and dicyclomine which were within the range of doses given to humans (Lexicomp, 1978 (Lexicomp, -2019a . We sacrificed mice when they reached 80% of their initial mass (survival endpoint). Dicyclomine at either a low or high dose did not affect mouse survival compared to PBStreatment. However, dicyclomine in combination with FLZ significantly improved survival over FLZ alone in a dose-dependent manner (Fig. 6M) , indicating that dicyclomine may not be effective at treating cryptococcosis on its own, but could well be of therapeutic benefit when combined with FLZ.
Discussion
Synergistic combination therapies are increasingly important clinical options, especially for drug resistant microbes (Cowen and Lindquist, 2005; Kalan and Wright, 2011; Uppuluri et al., 2008; Zheng et al., 2018) . Traditionally, synergistic drug pairs were discovered serendipitously, but new methods are improving our ability to uncover important interactions (Brown et al., 2014; Cokol et al., 2011; Cokol et al., 2018; Jansen et al., 2009; Robbins et al., 2015; Spitzer et al., 2011; Wambaugh et al., 2017; Wildenhain et al., 2015) . In this study, we identified a wide variety of molecules that interact synergistically with the antifungal FLZ to inhibit fungal growth. We do so without the use of noisy multi-drug assays, allowing for rapid and scalable screening. We also identify and investigate antagonistic interactions, which are clinically important (Khandeparkar and Rataboli, 2017; Vadlapatla et al., 2014) but have not been investigated in a systemic manner.
Of the 59 FLZ interacting molecules we identified, 10 have been previously described in various fungi, though 3 of those were reported as synergists while our testing revealed them to be antagonists (Ahmad et al., 2010; Butts et al., 2014; Cardoso et al., 2016; Eldesouky et al., 2018; Kang et al., 2010; Li et al., 2018; Marchetti et al., 2000; Quan et al., 2006; Robbins et al., 2015; Spitzer et al., 2011; Zhai et al., 2012) . Additionally, we discovered synergistic molecules with a wide variety of bioactivities, suggesting that O2M identifies synergistic molecules with molecular mechanisms that can differ from that of the starting synergistic pair. O2M analysis for FLZ synergizers used fenpropimorph and sertraline. Fenpropimorph inhibits ergosterol biosynthesis (Marcireau et al., 1990) and sertraline inhibits protein translation (Zhai et al., 2012) .
Furthermore, we identified broad spectrum interactions. All the combinations tested showed efficacy against multiple clinical and environmental isolates of C. neoformans, as well as C. deuterogattii, a related species which can cause disease in apparently immunocompetent individuals (Applen Clancey et al., 2019) . We also tested our combinations against common Candida species that often develop multi-drug resistance (Colombo et al., 2017) , including the emerging MDR pathogen Candida auris (Fig. 3) . Our data demonstrate that FLZ synergizers and antagonizers exhibit broad activities against multiple species and isolates.
Another key component of drug discovery is the ability to improve upon the efficacy of known drugs through synthetic modification and/or identification of structurally related molecules. We found that structural similarity predicts synergistic interactions ( Fig. S3) , just as drugs of similar structure have similar function. These data will open up our ability to rapidly identify many more synergizers and antagonizers from a single example.
We investigated the antagonistic interaction between FLZ and nafcillin, as nafcillin is a commonly used beta-lactam antibiotic for Staphylococcus aureus and other difficult to treat bacterial infections (Letourneau, 2019) . Patients with these infections include some of the same patients at risk for cryptococcosis (HIV and cancer patients) (Kaplan et al., 2009; Utay et al., 2016) and other fungal infections, including C. auris (Rudramurthy et al., 2017) . When we examined nafcillin-related molecules, we found that methicillin and oxacillin also antagonize FLZ. Furthermore, two cephalosporins often used in place of nafcillin, cefonicid and cefazolin, also unexpectedly antagonistize fluconazole activity. Nafcillin has previously been shown to adversely affect patients on the drug warfarin due to nafcillin's induction of cytochrome P450 (King et al., 2018) , which decreases warfarin concentration. This has been seen in a similar combination of FLZ and the antibiotic rifampicin (Panomvana Na Ayudhya et al., 2004) . Rifampicin is a potent inducer of drug metabolism due to elevation of hepatic cytochrome P450 through increased gene expression (Bolt, 2004) . This combination did indeed lower the serum levels of FLZ (Panomvana Na Ayudhya et al., 2004) , which resulted in relapse of cryptococcal meningitis (Coker et al., 1990) . We hypothesize that an analogous process occurs when nafcillin is combined with FLZ, with nafcillin increasing ergosterol biosynthesis enzymes, counteracting FLZ's activity. In a recent autopsy study, 10 or 16 patients who died of cryptococcosis were administered either a penicillin or a cephalosporin (Hurtado et al., 2019) . We recommend that these patients receive linezolid or vancomycin instead, since these drugs are used for similar bacterial targets but do not antagonize fluconazole activity (Fig. 4N) .
Our data demonstrate that O2M identifies promising new antifungal treatments that can rapidly move into the clinic. Our new combination of dicyclomine + FLZ almost doubled the median time-to-endpoint of mice treated with human dosages of dicyclomine ( Fig. 5M) , which is lower than dicyclomine's fungal MIC. Dicyclomine is orally bioavailable and able to cross the blood brain barrier (Das et al., 2013; Koerselman et al., 1999) , which makes it particularly promising for fungal meningitis treatment. Since dicyclomine, like many of our FLZ synergizers, is approved by the FDA for other indications, it could rapidly move into the clinic.
In sum, O2M considerably streamlined the identification of important drug interactions affecting C. neoformans growth. These interactions are both synergistic and antagonistic among multiple fungal species capable of causing disease in humans. We focused on FDA-approved molecules to bypass the time and considerable expense it takes to develop a new drug (Pushpakom et al., 2018) . However, our method would work equally well on any library of small molecules or biologic drugs to discover new antifungals. We showed that identifying these drug interactions can quickly lead to additional interacting pairs by examining structure (Fig. S3 ) or by investigating underlying mechanism (Wambaugh et al., 2017) . Finally, our newly discovered interaction of dicyclomine and FLZ exhibited therapeutic potential in vivo, demonstrating the clinical potential of fluconazole-containing synergistic pairs in the clinic.
Figure 1.
High-throughput screening for fluconazole interacting molecules using synergy prediction mutants. A) Outline of overlap 2 method (O2M), which is also presented in Brown et al. and Wambaugh et al. O2M requires a chemical-genetic dataset which can be generated by growing a collection of mutants in the presence of > 100 small molecules individually. Growth scores are then calculated for each small molecule + mutant combination. In the heatmaps, the vertical line represents a different mutant. Blue represents slower growth compared to wild-type cells and yellow represents faster growth compared to wild-type cells. Comparing our starting drug (FLZ) and known synergistic molecules, we can identify genes whose knockout mutants show similar growth scores to the starting drug and all known synergistic partners. These are the synergy prediction mutants. B) Screening method to identify molecules that synergize with FLZ as well as anti-C. neoformans molecules. These molecules are then validated in a checkerboard assay.
Figure 2. Synergistic and antagonistic molecules identified from high-throughput screen.
A) Fractional inhibitory concentration index (FICI) score of synergistic molecules identified from our high-throughput screen. Color of bar corresponds with bioactivities listed in C. B) Categories of bioactivities of synergistic molecules with the corresponding number of molecules in each category. C) FICI scores of antagonistic molecules from screen. Colors correspond with bioactivities listed in D. D) Categories of bioactivities of antagonistic molecules with corresponding number of molecules. All bioactivities came from Microsource Spectrum molecule list which is also seen in Table 1 . E) Representation of percentage of molecules predicted from the entire library (top), molecules tested in various assays (middle), and molecules yielding an interaction from checkerboards (bottom). * represents FICI for 50%inhibition of C. neoformans all other scores listed are the FICI for 90% inhibition (FICI90). 
Figure S1. Bliss independence scores of non-single agent molecules.
Average bliss independence score of molecules at 10 µM (A) and 100 nM (B). Molecules were considered synergistic if they exhibited a negative score in both concentrations the majority of times tested (green labels).
Figure S2. FICI scores of non-interacting molecules and general antifungals.
A) Fractional inhibitory concentration index (FICI) of molecules identified from our highthroughput screen that did not interact with FLZ. B) FICI scores of molecules identified as general anti-C. neoformans molecules from our high-throughput screen. Synergistic interactions with FLZ labeled in green and non-interacting molecules labeled in grey. * represents FICI for 50% inhibition of C. neoformans all others are FICI for 90% inhibition.
Figure S3. FICI scores of structurally similar molecules.
Chemical structure of dicyclomine HCl (A) and structurally similar molecules proadifen (B), drofenine (C) and naftidrofuryl (D). Chemical structure of desipramine HCl (E) and structurally similar molecules impramine (F), mianserine (G), and lofepramine (H). Chemical structure of sertraline HCl (I) and structurally similar sibutramine (J). Chemical structure of diphenhydramine HCl (K) and structurally similar citalopram (L). M) Fractional inhibitory concentration index (FICI) of structurally similar molecules. Synergistic interactions with FLZ labeled in green and noninteracting molecules labeled in grey. * represents FICI for 50% inhibition of C. neoformans all others listed are FICI for 90% inhibition. Table S1. Small molecules predicted to synergize with fluconazole by O2M. Small molecules predicted to interact with FLZ. Bioactivity and Status determined by Microsource Spectrum Library. INN, International Nonproprietary Names; USAN, United States Accepted Name; BAN, British Approved Names; JAN, Japanese Adopted Name; USP, United States Pharmacopeia; NF, National Formulary.
Table S2. Minimum inhibitory concentrations of non-interacting molecules.
Minimum inhibitory concentration for 50% inhibition (MIC 50) and 90% inhibition (MIC 90) of small molecules predicted to interact with FLZ but resulted in no interaction. Table S3 . Minimum inhibitory concentrations of general anti-C. neoformans molecules. Minimum inhibitory concentration 90% inhibition (MIC 90) for small molecules able to inhibit wild-type C. neoformans growth.
Table S4. Minimum inhibitory concentrations for various fungal strains/species.
Minimum inhibitory concentration for 50% inhibition (MIC 50) and 90% inhibition (MIC 90) of small molecules that interacted with FLZ in various fungal species. N/A represents molecules that did not have an MIC.
Table S4. Gene deletion mutants resistant to Dicyclomine.
Gene knockouts in KN99 resistant to dicyclomine at 1.65 mg/mL.
Methods

Fungal strains
Screening, validation, and structurally similar assays were performed with CM18 lab strain of C. neoformans. Screening with synergy prediction mutants (CNAG_00573Δ and CNAG_03917Δ) was in the CM18 background. Mechanistic studies were tested using the KN99 lab strain of C. neoformans. Clinical and environmental isolates of C. neoformans tested were a gift from Dr. John R. Perfect. C. deuterogattii strain R265 was purchased from ATCC. Candida albicans reference strain SC5314 and Candida glabrata reference strain CBS138 were used. Candida auris strains AR0383 and AR0384 were from the CDC.
Microsource Spectrum library screen
We inoculated either CM18 wild-type or CNAG_00573Δ or CNAG_03917Δ cells at 1000 cells per well of YNB + 2% glucose, then added small molecule to a final concentration of 1µM. Plates were incubated for 48 hours at 30 °C. OD600 was measured on the BioTek plate reader model Synergy H1. Small molecules that altered growth by absolute value 0.22 in both synergy prediction mutants was considered significant.
C. neoformans growth and small-molecule assays
All assays were performed in 1x YNB + 2% glucose. To determine MICs, an overnight culture was grown at 30 °C with rotation, diluted to OD600 = .02925 and 1000 cells were added to each well (2 µL of culture into 100 µL of media per well). Plates were incubated at 30 °C unless otherwise stated. Small molecule gradients were diluted in 2-fold dilution series. MIC values were calculated after 48 hours of incubation.
Checkerboard Assay and FICI calculations
We followed previously published methods (Hsieh et al., 1993; Orhan et al., 2005) . Starting inoculation of either fungal strain was 2µL of an OD600 = 0.02925 (1000 cells per well of 100 µL medium). Plates were grown statically for 48 hours at 30 °C with minor shaking/resuspension of cells at 24 and 48 hours. Checkerboards were read at 0 and 48 hours on a BioTek plate reader model Synergy H1 (Candida albicans and Candida glabrata were read at 0, 24, and 48 hours). Growth inhibition was assessed and FICIs for 50% and 90% inhibition were determined. Repeated results were averaged for the average FICI.
Bliss independence Assay
We created a gradient of fluconazole in a 96-well plate, then added small molecules at 10 µM or 100 nM final concentrations or vehicle. CM18 wild-type was added at 1000 cells per well of YNB+ 2% glucose. Percent growth was calculated for fluconazole, combinations, or small molecules alone. We then determined if growth inhibition caused by the combination was equal or greater than growth inhibition of the small molecules alone. The most repeatable result of multiple experiments was then averaged for average Bliss Independence Score.
Sterol extraction
KN99 culture was grown overnight in YNB + 2% glucose. Cells were sub-cultured into various treatments (vehicle control was YNB + 2% glucose). 6 ODs of each culture were harvested and lyophilized overnight. Pellets were resuspended in 25% alcoholic potassium hydroxide, vortexed, and incubated at 85 °C water bath for 1 hour. Water and n-heptane were added to each tube, vortexed, and the n-heptane layer was transferred to borosilicate glass tubes.
Metabolomics
Metabolomics analysis was performed at the Metabolomics Core Facility at the University of Utah which is supported by 1 S10 OD016232-01, 1 S10 OD021505-01, and 1 U54 DK110858-01.
Resistance to dicyclomine screen YNB + 2% glucose agar plates with or without 1.65 mg/mL of dicyclomine were made. Deletion mutants in KN99 strain were grown in YNB + 2% glucose then pinned to YNB plates. Plates were assessed at 1, 2, and 3 days for resistance.
Cell permeability assay
An overnight culture of KN99 was grown in YNB + 2% glucose. This was then sub-cultured into the various treatments (vehicle control was either 0.1% DMSO or only YNB + 2% glucose). Cultures were grown at 30 °C with rotation for 24 hours. Cultures were washed twice and resuspended in PBS. 3 µL of propidium iodide (stock concentration = 1 mg/mL) was added to the FACS tube. After 1 min flow cytometry was performed. Voltage gates used were as follows: FSC: 500; SSC: 310; PE: 496.
Resistance to toxic amino acids
An overnight culture of KN99 was grown in YNB + 2% glucose. This was sub-cultured into either dicyclomine (0.3 mg/mL), FLZ (3E-4 mg/mL), Synergy, or Vehicle (YNB + 2% glucose) and grown at 30 °C with rotation for 24 hours. Cells were then sub-cultured again into honeycomb plates with those previous treatments (dicylomine, FLZ, Synergy, or Vehicle) with either 20, 10, 5, 2.5 ug/mL of 5-FAA or 0.4 mg/mL 5-MT or vehicle (3.2% DMSO). Plates were read on a Bioscreen machine at 30 °C with OD600 measured every 30 minutes for 48 hours.
Calcofluor white flow cytometry
An overnight culture of KN99 was grown in YNB + 2% glucose then sub-cultured into either dicylomine, FLZ, Synergy, or Vehicle (YNB + 2% glucose) and grown at 30 °C with rotation for 24 hours. Cells were washed with PBS and calcofluor white added to a final concentration of 50 µg/mL and stained for 5-15 minutes. Cells were washed once more with PBS and assessed by flow cytometry. Voltage gates as follows: FSC: 500; SSC: 317; BV421-A: 185. Significance determined with Mann-Whitney test.
Murine model
~8-week-old female CD-1 ® IGS outbred mice (Charles River Laboratories) were intranasally inoculated with C. neoformans strain KN99 and monitored for survival as follows. The inoculum was prepared by culturing C. neoformans overnight in liquid YNB+2% glucose medium. C. neoformans cells collected from the overnight culture were washed twice in 1XPBS, counted, and suspended at a concentration of 5x10 5 cells / mL. Mice were anesthetized with ketamine/dexmedetomidine hydrochloride (Dexdomitor) administered intraperitoneally (i.p.) and suspended by their front incisors on a line of thread. The inoculum was delivered intranasally by pipetting 50 μL (2.5x10 4 cells / mouse) dropwise into the nostrils. After 10 minutes, mice were removed from the thread and were administered atipamezole (Antisedan) i.p. as a reversal agent. Mice were massed daily and euthanized by CO2 asphyxiation when they reached 80% of their initial mass. Beginning 8 days post-inoculation, they received daily i.p. injections of either 8 mg/kg FLZ, 1.15 mg/kg DIC, 2.30 mg/kg DIC, 8 mg/kg FLZ + 1.15 mg/kg DIC, 8 mg/kg FLZ + 2.30 mg/kg DIC, or PBS control (vehicle). Dosages were determined from human doses (Lexicomp, 1978 (Lexicomp, -2019a . Figure S1 . 
